Year: 2012
Type: article
Abstract: In neurodegenerative disorders, abnormally hyperphosphorylated and aggregated tau accumulates intracellularly, a mechanism which is thought to induce neuronal cell death. Methylene blue, a type of phenothiazine, has been reported to inhibit tau aggregation in vitro. However, the effect of methylene blue in vivo has remained unknown. Therefore, we examined whether methylene blue suppresses abnormal tau accumulation using P301L tau transgenic mice. At 8 to 11 months of age, these mice were orally administered methylene blue for 5 months. Subsequent results of Western blotting analysis revealed that this agent reduced detergent-insoluble phospho-tau. Methylene blue may have potential as a drug candidate for the treatment of tauopathy.
Source: PLoS ONE
Authors: Masato Hosokawa, Tetsuaki Arai, Masami Masuda-Suzukake, Takashi Nonaka, Makiko Yamashita, Haruhiko Akiyama, Masato Hasegawa
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,382
Awards: Development of novel therapeutic strategies against neurodegenerative diseases targeting on abnormal protein aggregates, Pathological study of abnormal protein accumulation and its propagation in the brain of patients with dementia, Molecular mechanisms of pathological protein propagation and its regulation, Pathological and biochemical study of dementia as a combined protein accumulation disease, Experimental research on the pathogenesis and pathophysiology of diseases that cause dementia, Creation of novel model mice for dementia research and development of new medicines for dementia treatment.
OpenAlex ID: W2071013059
